Home › Research › Risk genes beyond APOE
The amyloid precursor protein and its regulatory protein, FE65, in growth cones and synapses in vitro and in vivo
Sabo SL, Ikin AF, Buxbaum JD, Greengard P.. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003-07-01
Topic: Brain proteins, microglia and lab models
Although the Alzheimer amyloid protein precursor (APP) has been studied intensely for more than a decade, its function in neurons is unresolved. Much less is known about its binding partner FE65. We have shown recently that APP and FE65 synergistically regulate the movement of transfected cells.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sabo, S. L., Ikin, A. F., Buxbaum, J. D., & Greengard, P. (2003). The amyloid precursor protein and its regulatory protein, FE65, in growth cones and synapses in vitro and in vivo. The Journal of neuroscience : the official journal of the Society for Neuroscience. https://doi.org/10.1523/jneurosci.23-13-05407.2003
Vancouver
Sabo SL, Ikin AF, Buxbaum JD, Greengard P. The amyloid precursor protein and its regulatory protein, FE65, in growth cones and synapses in vitro and in vivo. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2003. doi:10.1523/jneurosci.23-13-05407.2003. PMID: 12843239.
BibTeX
@article{sabo2003-12843239,
author = {Sabo, S. L. and Ikin, A. F. and Buxbaum, J. D. and Greengard, P.},
title = {{The amyloid precursor protein and its regulatory protein, FE65, in growth cones and synapses in vitro and in vivo}},
journal = {The Journal of neuroscience : the official journal of the Society for Neuroscience},
year = {2003},
doi = {10.1523/jneurosci.23-13-05407.2003},
pmid = {12843239},
url = {https://doi.org/10.1523/jneurosci.23-13-05407.2003}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Much less is known about its binding partner FE65.
- We have shown recently that APP and FE65 synergistically regulate the movement of transfected cells.
- It remained to be shown whether endogenous APP and FE65 could play a similar role in vivo.
- Here, we show that FE65, like APP, is expressed at high levels in neurons.
Why it matters
This study shows that the protein FE65, like amyloid precursor protein (APP), is expressed at high levels in neurons, and that the two together regulate cell movement. It is basic laboratory work on normal protein function and does not test any treatment, cure or prevention for Alzheimer's disease.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Journal of neuroscience : the official journal of the Society for Neuroscience) |
| Journal's citation record | 4 / 4 | Journal of Neuroscience: journal h-index 651 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2003 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “in vitro”) — scores zero |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 187 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.5 citations a year over 25 year(s) since 2003 |
| Impact for its field and year | 3 / 6 | Cited 7.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Paul Greengard: h-index 206 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Icahn School of Medicine at Mount Sinai: institution h-index 1,331 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 12843239) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1523/jneurosci.23-13-05407.2003
- PubMed: 12843239
- Original source →
- Free full text: Journal of Neuroscience →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Risk genes beyond APOE
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.